# A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder

> **NCT05733390** · PHASE2 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Irritability Associated With Autism Spectrum Disorder
- Autism Spectrum Disorder
- ASD

## Interventions

- **DRUG:** JZP541
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05733390
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-30
- **Primary completion:** 2023-11-09
- **Final completion:** 2023-11-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** A decision has been made to prioritize other pipeline programs and terminate this study.
- **Last updated:** 2024-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733390, "A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05733390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*